Lynparza granted Priority Review in US

13th January 2020 Uncategorised 0

The first-in-class PARP inhibitor was also recently approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer.

More: Lynparza granted Priority Review in US
Source: News